65,437 trials
Epilepsy
Primary: Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment Period — 66.1; 66.6 percentage of participants
Familial Amyloid Polyneuropathy · Familial Amyloidosis
Primary: Neurologic Impairment Score + 7 (NIS+7) — 8.2; 26.3; 6.2; 12.5 units on a scale — p=<0.001
Idiopathic Pulmonary Fibrosis
Primary: Effect of Gefapixant on BP — 122; 76 units on a scale
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome (MDS)
Primary: Safety of HBO Administration in the Setting of UCB Stem Cell Transplantation — 15; 12; 12; 13 Participants
Kidney Disease
Primary: Variability of Tacrolimus Blood Levels Measured by DBS Over Time — 2.635 ng/ml
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Health Care Provider Education
Primary: Change in Test Scores on Knowledge of Course Content From Baseline to 30 Days — 39.3 units on a scale
Bipolar Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — 7.4; 7.9 UNITS ON A SCALE
Acute Non-complicated Postural Neck Pain
Primary: Change in Cervical Range of Motion — 37.9; 36.9; 39.5; 37.5 degrees
Carcinoma, Basal Cell · Carcinoma, Squamous Cell · Skin Neoplasms
Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93
Aplastic Anemia
Primary: Incidence of Chronic GVHD — 5 number participants with chronic GVHD
Esophageal Cancer
Primary: Progression Free Survival Rate at 24 Weeks — 25 percentage of participants
Neuroblastoma
Primary: Maximum Tolerated Dose — 18.6 mCi/kg
Juvenile Idiopathic Arthritis
Primary: Minimum Serum Concentration (Cmin) of TCZ at Steady State — 13.35; 12.71 Micrograms/milliliter (mcg/mL)
Cervical Dystonia
Primary: Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4. — 42.5; 42.4; 31.7; 39.9 units on a scale — p=<0.001